Nothing Special   »   [go: up one dir, main page]

Castello et al., 2020 - Google Patents

Circulating tumor cells and metabolic parameters in NSCLC patients treated with checkpoint inhibitors

Castello et al., 2020

View HTML
Document ID
16181092661870221009
Author
Castello A
Carbone F
Rossi S
Monterisi S
Federico D
Toschi L
Lopci E
Publication year
Publication venue
Cancers

External Links

Snippet

Circulating tumor cells (CTC) count and characterization have been associated with poor prognosis in recent studies. Our aim was to examine CTC count and its association with metabolic parameters and clinical outcomes in non-small cell lung carcinoma (NSCLC) …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/10—Services
    • G06Q50/22—Health care, e.g. hospitals; Social work
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/01—Social networking
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06F—ELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using infra-red, visible or ultra-violet light
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING; COUNTING
    • G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q10/00—Administration; Management

Similar Documents

Publication Publication Date Title
Echarti et al. CD8+ and regulatory T cells differentiate tumor immune phenotypes and predict survival in locally advanced head and neck cancer
Castello et al. Circulating tumor cells and metabolic parameters in NSCLC patients treated with checkpoint inhibitors
Wu et al. Circulating tumor cells as a tool of minimal residual disease can predict lung cancer recurrence: a longitudinal, prospective trial
Alama et al. Prognostic relevance of circulating tumor cells and circulating cell-free DNA association in metastatic non-small cell lung cancer treated with nivolumab
Botticelli et al. The role of soluble LAG3 and soluble immune checkpoints profile in advanced head and neck cancer: a pilot study
Agashe et al. Circulating tumor cells: From the laboratory to the cancer clinic
Reduzzi et al. Circulating tumor cell clusters are frequently detected in women with early-stage breast cancer
Komuta Histological heterogeneity of primary liver cancers: clinical relevance, diagnostic pitfalls and the pathologist’s role
Rapoport et al. Tumor-infiltrating lymphocytes (Tils) in early breast cancer patients: High Cd3+, Cd8+, and immunoscore are associated with a pathological complete response
Deutsch et al. Cut-off analysis of CTC change under systemic therapy for defining early therapy response in metastatic breast cancer
Gow et al. Clinicopathological features and survival outcomes of primary pulmonary invasive mucinous adenocarcinoma
Schnellhardt et al. Tumour-infiltrating inflammatory cells in early breast cancer: an underrated prognostic and predictive factor?
Katsarou et al. Detyrosinated α-tubulin, vimentin and PD-L1 in circulating tumor cells (CTCs) isolated from non-small cell lung cancer (NSCLC) patients
Conteduca et al. Plasma androgen receptor in prostate cancer
Bonosi et al. Liquid biopsy in diagnosis and prognosis of high-grade gliomas; state-of-the-art and literature review
Pantano et al. Large-scale profiling of extracellular vesicles identified miR-625-5p as a novel biomarker of immunotherapy response in advanced non-small-cell lung cancer patients
Tang et al. Clinical applications of cancer-associated cells present in the blood of cancer patients
Raimondi et al. PD-L1 expression on circulating tumour cells may be predictive of response to regorafenib in patients diagnosed with chemorefractory metastatic colorectal cancer
Narbe et al. The distribution of circulating tumor cells is different in metastatic lobular compared to ductal carcinoma of the breast—long-term prognostic significance
Shalata et al. Multi-center real-world outcomes of nivolumab plus ipilimumab and chemotherapy in patients with metastatic non-small-cell lung cancer
Koinis et al. Prognostic role of circulating tumor cells in patients with metastatic castration-resistant prostate cancer receiving cabazitaxel: a prospective biomarker study
Agostinetto et al. Post-neoadjuvant treatment strategies for patients with early breast cancer
Yang et al. Significance of phosphorylated epidermal growth factor receptor and its signal transducers in human soft tissue sarcoma
Isebia et al. Characterizing circulating tumor cells and tumor-derived extracellular vesicles in metastatic castration-naive and castration-resistant prostate cancer patients
Bumes et al. Validation study for non-invasive prediction of IDH mutation status in patients with glioma using in vivo 1H-magnetic resonance spectroscopy and machine learning